Mayne Pharma Group (MYX) Investor presentation summary

FY26 performance

• FY26 revenue A$383.7m, down 6% YoY; gross margin 64.7%, vs 60.6% in FY25; underlying EBITDA A$34.2m, down 27%.

• Total direct segment contribution A$107.1m, down 2%; adjusted operating cash flow A$34.5m, down 24%; cash and marketable securities A$80.0m at 30 June 2026.

• Branded products rose to 83% of net sales in FY26, from 79% in FY25 and 68% in FY24; gross margin increased to 65%, from 61% and 56%, respectively.

• FY26 revenue mix: Women's Health A$174.3m (46%), Dermatology/DistributeRx A$138.7m (36%) and International A$70.7m (18%).

1Q FY27 results

• Revenue A$95.7m, down 2% YoY; gross margin 63%, vs 67%; underlying EBITDA A$5.3m, down 52%; direct segment contribution A$23.3m, down 23%.

• Adjusted operating cash flow from continuing operations was -A$2.1m, vs +A$6.6m in 1Q FY26; cash and marketable securities were A$67.3m at 30 September 2026.

• Women's Health revenue US$34.4m, up 9% YoY, and direct contribution US$12.8m, up 4%; Dermatology/DistributeRx revenue US$18.9m, down 16%, and contribution US$3.1m, down 61%.

• International revenue US$20.2m, up 13% YoY; gross profit US$6.1m, up 3%, at 31% gross margin; direct contribution US$1.4m, down 5%.

Women's health

• NEXTSTELLIS demand cycles rose 27% YoY and net sales reached US$14.7m, up 17%; new PBM coverage from 1 August brought total coverage to ~128m lives.

• BIJUVA prescriptions rose 25% YoY and net sales 8% to US$4.5m; IMVEXXY prescriptions rose 13% and net sales 39% to US$8.5m; ANNOVERA prescriptions fell 1% and net sales 27% to US$5.9m.

• FY26 NEXTSTELLIS cycles increased 15% YoY and net sales rose 6% to US$45.2m; ANNOVERA net sales fell 13% to US$25.7m amid returns challenges.